Literature DB >> 12467062

Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.

Roberto Casella1, Shahrokh F Shariat, Mara A Monoski, Seth P Lerner.   

Abstract

BACKGROUND: The authors found previously that plasma levels of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. In the current study, they tested the hypothesis that elevated urinary levels of uPA and uPAR would predict the presence of bladder malignancy by comparing the performance of uPA and uPAR with the performance of bladder wash-out cytology in the noninvasive diagnosis of bladder tumors.
METHODS: An enzyme-linked immunosorbent assay was used to compare levels of uPA and uPAR in urine that was collected before cystoscopy from 122 patients with bladder carcinoma and from 107 participants in a control group. Seventy-two patients had clinical Tis or Ta transitional cell carcinoma, and 50 patients had invasive disease (>or= T1); 85 patients had clinical Grade 1-2 tumors, and 37 patients had Grade 3 tumors. For cytology, only high grade was considered positive.
RESULTS: Urinary levels of uPA and uPAR were higher in patients with bladder carcinoma compared with levels in the control group (P < 0.001 and P = 0.016, respectively). However, only uPA levels were elevated in patients with abnormal urinary cytology (P = 0.006). After controlling for cytology (odds ratio [OR], 10.182; 95% confidence interval [95%CI], 4.451-23.291; P < 0.001), uPAR (P for trend = 0.168), and age (P = 0.091), those in the highest quartile for uPA had an increased risk of bladder carcinoma compared with those in the lowest quartile (OR, 3.022; 95%CI, 1.295-7.054; P for trend = 0.031).
CONCLUSIONS: The current findings suggest that urinary levels of uPA, but not uPAR, are related to the risk of bladder carcinoma. The study confirmed the central role of urinary cytology in the noninvasive diagnosis of bladder carcinoma. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10989

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467062     DOI: 10.1002/cncr.10989

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Formyl peptide receptor-like proteins are a novel family of vomeronasal chemosensors.

Authors:  Stéphane Rivière; Ludivine Challet; Daniela Fluegge; Marc Spehr; Ivan Rodriguez
Journal:  Nature       Date:  2009-05-28       Impact factor: 49.962

Review 2.  Alternatives to cytology in the management of non-muscle invasive bladder cancer.

Authors:  Gilad E Amiel; Tung Shu; Seth P Lerner
Journal:  Curr Treat Options Oncol       Date:  2004-10

Review 3.  Non-invasive methods of bladder cancer detection.

Authors:  Brian Little
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

4.  Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.

Authors:  Claudio Sorio; Andrea Mafficini; Federico Furlan; Stefano Barbi; Antonio Bonora; Giorgio Brocco; Francesco Blasi; Giorgio Talamini; Claudio Bassi; Aldo Scarpa
Journal:  BMC Cancer       Date:  2011-10-14       Impact factor: 4.430

5.  uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.

Authors:  Line Hammer Dohn; Helle Pappot; Benedikte Richter Iversen; Martin Illemann; Gunilla Høyer-Hansen; Ib Jarle Christensen; Peter Thind; Lisbeth Salling; Hans von der Maase; Ole Didrik Laerum
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.